Brokers Offer Predictions for RCKT Q2 Earnings

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) – Research analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for shares of Rocket Pharmaceuticals in a note issued to investors on Thursday, February 27th. Leerink Partnrs analyst M. Foroohar anticipates that the biotechnology company will post earnings of ($0.51) per share for the quarter. The consensus estimate for Rocket Pharmaceuticals’ current full-year earnings is ($2.83) per share. Leerink Partnrs also issued estimates for Rocket Pharmaceuticals’ Q4 2025 earnings at ($0.50) EPS.

RCKT has been the subject of several other reports. Wedbush began coverage on shares of Rocket Pharmaceuticals in a research report on Monday, December 30th. They set an “outperform” rating and a $32.00 price objective for the company. The Goldman Sachs Group reduced their target price on shares of Rocket Pharmaceuticals from $29.00 to $15.00 and set a “neutral” rating for the company in a report on Monday. Canaccord Genuity Group reduced their target price on shares of Rocket Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating for the company in a report on Monday. Jefferies Financial Group began coverage on shares of Rocket Pharmaceuticals in a report on Wednesday, December 18th. They issued a “buy” rating and a $29.00 target price for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 target price on shares of Rocket Pharmaceuticals in a report on Tuesday, November 19th. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, Rocket Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $42.30.

Rocket Pharmaceuticals Price Performance

Rocket Pharmaceuticals stock opened at $8.66 on Monday. The stock has a market cap of $789.42 million, a P/E ratio of -3.15 and a beta of 0.98. The company has a fifty day simple moving average of $10.84 and a 200-day simple moving average of $14.59. Rocket Pharmaceuticals has a 12-month low of $8.25 and a 12-month high of $28.73. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06.

Rocket Pharmaceuticals (NASDAQ:RCKT) last released its quarterly earnings data on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.06.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC grew its position in Rocket Pharmaceuticals by 796.2% during the fourth quarter. SG Americas Securities LLC now owns 54,921 shares of the biotechnology company’s stock worth $690,000 after buying an additional 48,793 shares during the period. Jennison Associates LLC grew its position in Rocket Pharmaceuticals by 72.6% during the fourth quarter. Jennison Associates LLC now owns 70,304 shares of the biotechnology company’s stock worth $884,000 after buying an additional 29,564 shares during the period. Mirador Capital Partners LP grew its position in Rocket Pharmaceuticals by 403.9% during the fourth quarter. Mirador Capital Partners LP now owns 84,529 shares of the biotechnology company’s stock worth $1,063,000 after buying an additional 67,755 shares during the period. First Turn Management LLC grew its position in Rocket Pharmaceuticals by 10.8% during the third quarter. First Turn Management LLC now owns 621,306 shares of the biotechnology company’s stock worth $11,476,000 after buying an additional 60,317 shares during the period. Finally, Sovran Advisors LLC acquired a new position in Rocket Pharmaceuticals during the fourth quarter worth about $1,895,000. 98.39% of the stock is currently owned by institutional investors and hedge funds.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.